PubRank

K Kian Ang

Author PubWeight™ 196.08‹?›

Top papers

Rank Title Journal Year PubWeight™‹?›
1 Radiotherapy plus cetuximab for squamous-cell carcinoma of the head and neck. N Engl J Med 2006 25.67
2 Radiotherapy plus cetuximab for locoregionally advanced head and neck cancer: 5-year survival data from a phase 3 randomised trial, and relation between cetuximab-induced rash and survival. Lancet Oncol 2009 8.46
3 Randomized phase III trial of concurrent accelerated radiation plus cisplatin with or without cetuximab for stage III to IV head and neck carcinoma: RTOG 0522. J Clin Oncol 2014 5.80
4 Factors associated with severe late toxicity after concurrent chemoradiation for locally advanced head and neck cancer: an RTOG analysis. J Clin Oncol 2008 4.39
5 Validation of an accelerated 'demons' algorithm for deformable image registration in radiation therapy. Phys Med Biol 2005 4.00
6 Intensity-modulated radiation therapy with or without chemotherapy for nasopharyngeal carcinoma: radiation therapy oncology group phase II trial 0225. J Clin Oncol 2009 3.99
7 Hypoxia-inducible mir-210 regulates normoxic gene expression involved in tumor initiation. Mol Cell 2009 3.68
8 An epithelial-mesenchymal transition gene signature predicts resistance to EGFR and PI3K inhibitors and identifies Axl as a therapeutic target for overcoming EGFR inhibitor resistance. Clin Cancer Res 2012 3.48
9 Quantification of volumetric and geometric changes occurring during fractionated radiotherapy for head-and-neck cancer using an integrated CT/linear accelerator system. Int J Radiat Oncol Biol Phys 2004 3.21
10 Tobacco smoking and increased risk of death and progression for patients with p16-positive and p16-negative oropharyngeal cancer. J Clin Oncol 2012 3.04
11 American Society of Clinical Oncology clinical practice guideline for the use of larynx-preservation strategies in the treatment of laryngeal cancer. J Clin Oncol 2006 2.68
12 Models for evaluating agents intended for the prophylaxis, mitigation and treatment of radiation injuries. Report of an NCI Workshop, December 3-4, 2003. Radiat Res 2004 2.33
13 Prediction of neck dissection requirement after definitive radiotherapy for head-and-neck squamous cell carcinoma. Int J Radiat Oncol Biol Phys 2012 2.14
14 Gene expression profiles identify epithelial-to-mesenchymal transition and activation of nuclear factor-kappaB signaling as characteristics of a high-risk head and neck squamous cell carcinoma. Cancer Res 2006 2.13
15 Oropharyngeal carcinoma related to human papillomavirus. BMJ 2010 2.09
16 Addition of bevacizumab to standard chemoradiation for locoregionally advanced nasopharyngeal carcinoma (RTOG 0615): a phase 2 multi-institutional trial. Lancet Oncol 2011 2.03
17 TAME: development of a new method for summarising adverse events of cancer treatment by the Radiation Therapy Oncology Group. Lancet Oncol 2007 2.03
18 Multi-institutional trial of accelerated hypofractionated intensity-modulated radiation therapy for early-stage oropharyngeal cancer (RTOG 00-22). Int J Radiat Oncol Biol Phys 2009 1.88
19 Disease-control rates following intensity-modulated radiation therapy for small primary oropharyngeal carcinoma. Int J Radiat Oncol Biol Phys 2006 1.85
20 The epidermal growth factor receptor mediates radioresistance. Int J Radiat Oncol Biol Phys 2003 1.83
21 Long-term follow-up of the RTOG 9501/intergroup phase III trial: postoperative concurrent radiation therapy and chemotherapy in high-risk squamous cell carcinoma of the head and neck. Int J Radiat Oncol Biol Phys 2012 1.77
22 Larynx preservation clinical trial design: key issues and recommendations-a consensus panel summary. Int J Radiat Oncol Biol Phys 2009 1.75
23 Multiple regions-of-interest analysis of setup uncertainties for head-and-neck cancer radiotherapy. Int J Radiat Oncol Biol Phys 2006 1.75
24 TP53 disruptive mutations lead to head and neck cancer treatment failure through inhibition of radiation-induced senescence. Clin Cancer Res 2011 1.71
25 Quality of life in head and neck cancer patients after treatment with high-dose radiotherapy alone or in combination with cetuximab. J Clin Oncol 2007 1.66
26 Prospective risk-adjusted [18F]Fluorodeoxyglucose positron emission tomography and computed tomography assessment of radiation response in head and neck cancer. J Clin Oncol 2009 1.66
27 Measuring head and neck cancer symptom burden: the development and validation of the M. D. Anderson symptom inventory, head and neck module. Head Neck 2007 1.63
28 Immunohistochemically determined total epidermal growth factor receptor levels not of prognostic value in newly diagnosed glioblastoma multiforme: report from the Radiation Therapy Oncology Group. Int J Radiat Oncol Biol Phys 2005 1.60
29 Sensitization of breast cancer cells to radiation by trastuzumab. Mol Cancer Ther 2003 1.56
30 IMRT reirradiation of head and neck cancer-disease control and morbidity outcomes. Int J Radiat Oncol Biol Phys 2008 1.51
31 Beam path toxicities to non-target structures during intensity-modulated radiation therapy for head and neck cancer. Int J Radiat Oncol Biol Phys 2008 1.51
32 Use of deformed intensity distributions for on-line modification of image-guided IMRT to account for interfractional anatomic changes. Int J Radiat Oncol Biol Phys 2005 1.49
33 Candidate dosimetric predictors of long-term swallowing dysfunction after oropharyngeal intensity-modulated radiotherapy. Int J Radiat Oncol Biol Phys 2010 1.49
34 Determining optimal clinical target volume margins in head-and-neck cancer based on microscopic extracapsular extension of metastatic neck nodes. Int J Radiat Oncol Biol Phys 2005 1.47
35 Is concurrent chemoradiation the treatment of choice for all patients with Stage III or IV head and neck carcinoma? Cancer 2004 1.43
36 Sinonasal malignancies with neuroendocrine differentiation: patterns of failure according to histologic phenotype. Cancer 2004 1.43
37 The epidemic of HPV-associated oropharyngeal cancer is here: is it time to change our treatment paradigms? J Natl Compr Canc Netw 2011 1.39
38 miRNA expression profiles in head and neck squamous cell carcinoma and adjacent normal tissue. Head Neck 2009 1.38
39 Epidermal growth factor receptor and tumor response to radiation: in vivo preclinical studies. Int J Radiat Oncol Biol Phys 2004 1.32
40 Management of nonsinonasal neuroendocrine carcinomas of the head and neck. Cancer 2003 1.24
41 Postoperative external beam radiotherapy for differentiated thyroid cancer: outcomes and morbidity with conformal treatment. Int J Radiat Oncol Biol Phys 2008 1.23
42 Patterns of disease recurrence following treatment of oropharyngeal cancer with intensity modulated radiation therapy. Int J Radiat Oncol Biol Phys 2012 1.23
43 Intensity-modulated radiation therapy (IMRT) of cancers of the head and neck: comparison of split-field and whole-field techniques. Int J Radiat Oncol Biol Phys 2005 1.23
44 Cyclin B1 overexpression and resistance to radiotherapy in head and neck squamous cell carcinoma. Cancer Res 2002 1.21
45 Receptor signaling as a regulatory mechanism of DNA repair. Radiother Oncol 2009 1.19
46 Importance of patient examination to clinical quality assurance in head and neck radiation oncology. Head Neck 2006 1.18
47 Long-term results of concomitant boost radiation plus concurrent cisplatin for advanced head and neck carcinomas: a phase II trial of the radiation therapy oncology group (RTOG 99-14). Int J Radiat Oncol Biol Phys 2008 1.18
48 Integrating epidermal growth factor receptor assay with clinical parameters improves risk classification for relapse and survival in head-and-neck squamous cell carcinoma. Int J Radiat Oncol Biol Phys 2010 1.16
49 Endostatin improves radioresponse and blocks tumor revascularization after radiation therapy for A431 xenografts in mice. Int J Radiat Oncol Biol Phys 2007 1.13
50 Accumulation of the common mitochondrial DNA deletion induced by ionizing radiation. FEBS Lett 2004 1.13
51 C225 antiepidermal growth factor receptor antibody enhances the efficacy of docetaxel chemoradiotherapy. Int J Radiat Oncol Biol Phys 2004 1.10
52 DNA repair biomarker profiling of head and neck cancer: Ku80 expression predicts locoregional failure and death following radiotherapy. Clin Cancer Res 2011 1.08
53 Overexpression of S100A2 protein as a prognostic marker for patients with stage I non small cell lung cancer. Int J Cancer 2005 1.07
54 Results of radiotherapy for T2N0 glottic carcinoma: does the "2" stand for twice-daily treatment? Int J Radiat Oncol Biol Phys 2003 1.06
55 Outcomes and patterns of care of patients with locally advanced oropharyngeal carcinoma treated in the early 21st century. Radiat Oncol 2013 1.06
56 Larynx preservation clinical trial design: key issues and recommendations--a consensus panel summary. Head Neck 2009 1.05
57 The M. D. Anderson symptom inventory-head and neck module, a patient-reported outcome instrument, accurately predicts the severity of radiation-induced mucositis. Int J Radiat Oncol Biol Phys 2008 1.05
58 Targeting the phosphatidylinositol 3-kinase/Akt pathway for enhancing breast cancer cells to radiotherapy. Mol Cancer Ther 2003 1.03
59 Radiation dosimetry of 99mTc-labeled C225 in patients with squamous cell carcinoma of the head and neck. J Nucl Med 2004 1.03
60 Serum signature of hypoxia-regulated factors is associated with progression after induction therapy in head and neck squamous cell cancer. Mol Cancer Ther 2010 1.03
61 A multinational, randomized phase III trial of iseganan HCl oral solution for reducing the severity of oral mucositis in patients receiving radiotherapy for head-and-neck malignancy. Int J Radiat Oncol Biol Phys 2004 1.01
62 Simple carotid-sparing intensity-modulated radiotherapy technique and preliminary experience for T1-2 glottic cancer. Int J Radiat Oncol Biol Phys 2009 1.01
63 Longitudinal Oncology Registry of Head and Neck Carcinoma (LORHAN): analysis of chemoradiation treatment approaches in the United States. Cancer 2010 1.00
64 Validation of lysyl oxidase as a prognostic marker for metastasis and survival in head and neck squamous cell carcinoma: Radiation Therapy Oncology Group trial 90-03. J Clin Oncol 2009 1.00
65 Radiotherapy for cancer of the head and neck: altered fractionation regimens. Lancet Oncol 2002 1.00
66 Evaluation of tumor angiogenesis measured with microvessel density (MVD) as a prognostic indicator in nasopharyngeal carcinoma: results of RTOG 9505. Int J Radiat Oncol Biol Phys 2005 1.00
67 An evaluation of the variability of tumor-shape definition derived by experienced observers from CT images of supraglottic carcinomas (ACRIN protocol 6658). Int J Radiat Oncol Biol Phys 2007 0.99
68 Use of molecular biomarkers for predicting the response to radiotherapy with or without chemotherapy. J Clin Oncol 2007 0.98
69 Importance of maintenance therapy in C225-induced enhancement of tumor control by fractionated radiation. Int J Radiat Oncol Biol Phys 2007 0.97
70 Improved survival using intensity-modulated radiation therapy in head and neck cancers: a SEER-Medicare analysis. Cancer 2014 0.96
71 Dasatinib, a multi-kinase inhibitor increased radiation sensitivity by interfering with nuclear localization of epidermal growth factor receptor and by blocking DNA repair pathways. Radiother Oncol 2012 0.95
72 The prognostic value of nestin expression in newly diagnosed glioblastoma: report from the Radiation Therapy Oncology Group. Radiat Oncol 2008 0.95
73 Concurrent radiation chemotherapy for locally advanced head and neck carcinoma: are we addressing burning subjects? J Clin Oncol 2004 0.95
74 Phase I/II study of docetaxel, cisplatin, and concomitant boost radiation for locally advanced squamous cell cancer of the head and neck. J Clin Oncol 2006 0.94
75 Prospective imaging assessment of mortality risk after head-and-neck radiotherapy. Int J Radiat Oncol Biol Phys 2010 0.93
76 Early postoperative paclitaxel followed by concurrent paclitaxel and cisplatin with radiation therapy for patients with resected high-risk head and neck squamous cell carcinoma: report of the phase II trial RTOG 0024. J Clin Oncol 2009 0.93
77 Glioma-associated oncogene family zinc finger 1 expression and metastasis in patients with head and neck squamous cell carcinoma treated with radiation therapy (RTOG 9003). J Clin Oncol 2011 0.92
78 Molecular signatures associated with clinical outcome in patients with high-risk head-and-neck squamous cell carcinoma treated by surgery and radiation. Int J Radiat Oncol Biol Phys 2005 0.92
79 Epidermal growth factor receptor expression correlates with poor survival in patients who have breast carcinoma treated with doxorubicin-based neoadjuvant chemotherapy. Cancer 2005 0.92
80 Intensity-modulated radiotherapy for cervical node squamous cell carcinoma metastases from unknown head-and-neck primary site: M. D. Anderson Cancer Center outcomes and patterns of failure. Int J Radiat Oncol Biol Phys 2010 0.92
81 Combination of radiotherapy with EGFR antagonists for head and neck carcinoma. Int J Clin Oncol 2007 0.91
82 Outcomes after radiotherapy for squamous cell carcinoma of the eyelid. Cancer 2008 0.91
83 Target coverage for head and neck cancers treated with IMRT: review of clinical experiences. Semin Radiat Oncol 2004 0.90
84 Radiotherapy for cutaneous malignant melanoma: rationale and indications. Oncology (Williston Park) 2004 0.88
85 Radiation therapy for early-stage carcinoma of the oropharynx. Int J Radiat Oncol Biol Phys 2004 0.88
86 Long-term outcomes after surgical or nonsurgical initial therapy for patients with T4 squamous cell carcinoma of the larynx: A 3-decade survey. Cancer 2015 0.88
87 Hypopharyngeal dose is associated with severe late toxicity in locally advanced head-and-neck cancer: an RTOG analysis. Int J Radiat Oncol Biol Phys 2012 0.88
88 Outcomes of malignant tumors of the lacrimal apparatus: the University of Texas MD Anderson Cancer Center experience. Cancer 2011 0.88
89 Epidermal growth factor receptor as a target to improve treatment of lung cancer. Clin Lung Cancer 2004 0.88
90 Combination of anti-IGF-1R antibody A12 and ionizing radiation in upper respiratory tract cancers. Int J Radiat Oncol Biol Phys 2010 0.88
91 Postoperative radiotherapy for maxillary sinus cancer: long-term outcomes and toxicities of treatment. Int J Radiat Oncol Biol Phys 2007 0.87
92 Relationship between cyclin D1 expression and poor radioresponse of murine carcinomas. Int J Radiat Oncol Biol Phys 2002 0.87
93 MK-4827, a PARP-1/-2 inhibitor, strongly enhances response of human lung and breast cancer xenografts to radiation. Invest New Drugs 2011 0.87
94 Flavopiridol, a cyclin-dependent kinase inhibitor, enhances radiosensitivity of ovarian carcinoma cells. Cancer Res 2003 0.86
95 Integrating radiotherapy with epidermal growth factor receptor antagonists and other molecular therapeutics for the treatment of head and neck cancer. Int J Radiat Oncol Biol Phys 2007 0.86
96 An international collaboration to harmonize the quantitative plasma Epstein-Barr virus DNA assay for future biomarker-guided trials in nasopharyngeal carcinoma. Clin Cancer Res 2013 0.85
97 Assessment of epidermal growth factor receptor with 99mTc-ethylenedicysteine-C225 monoclonal antibody. Anticancer Drugs 2003 0.85
98 Outcomes after radiotherapy for basaloid squamous cell carcinoma of the head and neck: a case-control study. Cancer 2008 0.85
99 Long-term radiotherapy outcomes for nasal cavity and septal cancers. Int J Radiat Oncol Biol Phys 2007 0.85
100 Cervical lymph node metastases from occult squamous cell carcinoma. Curr Treat Options Oncol 2002 0.84
101 Elective radiotherapy provides regional control for patients with cutaneous melanoma of the head and neck. Cancer 2004 0.83
102 The role of apoptosis in radiation oncology. Int J Radiat Biol 2009 0.83
103 The effect of dental artifacts, contrast media, and experience on interobserver contouring variations in head and neck anatomy. Am J Clin Oncol 2007 0.83
104 A phase II study of submandibular gland transfer prior to radiation for prevention of radiation-induced xerostomia in head-and-neck cancer (RTOG 0244). Int J Radiat Oncol Biol Phys 2012 0.83
105 The impact of timing of EGFR and IGF-1R inhibition for sensitizing head and neck cancer to radiation. Anticancer Res 2012 0.82
106 Toward improving the therapeutic ratio in stereotactic radiosurgery: selective modulation of the radiation responses of both normal tissues and tumor. J Neurosurg 2007 0.82
107 Melanoma metastatic to cervical lymph nodes: Can radiotherapy replace formal dissection after local excision of nodal disease? Head Neck 2005 0.82
108 Longitudinal oncology registry of head and neck carcinoma (LORHAN): initial supportive care findings. Support Care Cancer 2009 0.82
109 Targeted therapies and radiation for the treatment of head and neck cancer: are we making progress? Semin Radiat Oncol 2004 0.82
110 Loss of Fhit expression in head and neck squamous cell carcinoma and its potential clinical implication. Clin Cancer Res 2004 0.82
111 A phase I/II study of neoadjuvant chemotherapy followed by radiation with boost chemotherapy for advanced T-stage nasopharyngeal carcinoma. Int J Radiat Oncol Biol Phys 2005 0.82
112 AC480, formerly BMS-599626, a pan Her inhibitor, enhances radiosensitivity and radioresponse of head and neck squamous cell carcinoma cells in vitro and in vivo. Invest New Drugs 2010 0.82
113 Combining molecular therapeutics with radiotherapy for head and neck cancer. J Surg Oncol 2008 0.81
114 Altered radiation therapy fractionation, chemoradiation, and patient selection for the treatment of head and neck squamous carcinoma. Semin Radiat Oncol 2004 0.81
115 Radiation therapy for malignant melanoma. Surg Clin North Am 2003 0.81
116 Intensity-modulated radiotherapy: is xerostomia still prevalent? Curr Oncol Rep 2005 0.80
117 Two-field versus three-field irradiation technique in the postoperative treatment of head-and-neck cancer. Int J Radiat Oncol Biol Phys 2006 0.80
118 Microvessel density >or=60 does not predict for outcome after radiation treatment for locally advanced head and neck squamous cell carcinoma: results of a correlative study from the Radiation Therapy Oncology Group (RTOG) 90-03 Trial. Am J Clin Oncol 2007 0.79
119 Management of human papillomavirus-positive and human papillomavirus-negative head and neck cancer. Semin Radiat Oncol 2012 0.79
120 Strategic plans to promote head and neck cancer translational research within the radiation therapy oncology group: a report from the translational research program. Int J Radiat Oncol Biol Phys 2007 0.78
121 More lessons learned from the suffocation of hypoxia. J Clin Oncol 2010 0.78
122 Defining molecular and cellular responses after low and high linear energy transfer radiations to develop biomarkers of carcinogenic risk or therapeutic outcome. Health Phys 2012 0.78
123 A phase I study of fludarabine combined with radiotherapy in patients with intermediate to locally advanced head and neck squamous cell carcinoma. Radiother Oncol 2002 0.78
124 The American Board of Radiology Holman Research Pathway: 10-year retrospective review of the program and participant performance. Int J Radiat Oncol Biol Phys 2012 0.78
125 Effects of insulin-like growth factor-1 (IGF-1) and amifostine in spinal cord reirradiation. Strahlenther Onkol 2005 0.77
126 Enhanced response to C225 of A431 tumor xenografts growing in irradiated tumor bed. Radiother Oncol 2009 0.77
127 Residual nodal disease in patients with advanced-stage oropharyngeal squamous cell carcinoma treated with definitive radiation therapy and posttreatment neck dissection: Association with locoregional recurrence, distant metastasis, and decreased survival. Head Neck 2012 0.77
128 Modulation of rodent spinal cord radiation tolerance by administration of platelet-derived growth factor. Int J Radiat Oncol Biol Phys 2004 0.76
129 Concomitant chemotherapy and radiation therapy certainly improves local control. Int J Radiat Oncol Biol Phys 2005 0.76
130 [Experimental data for administration of insulin-like growth factor 1 (IGF-1) and basic fibroblast growth factor (bFGF) for prevention of radiation myelopathy]. Strahlenther Onkol 2002 0.76
131 Blasted cell line names. Cancer Inform 2010 0.75
132 Innovative prevention strategies for radiation necrosis of the central nervous system. Anticancer Res 2002 0.75
133 P105 as a prognostic indicator in patients irradiated for locally advanced head-and-neck cancer: a clinical/laboratory correlative analysis of RTOG-9003. Int J Radiat Oncol Biol Phys 2003 0.75
134 Feasibility of economic analysis of Radiation Therapy Oncology Group (RTOG) 91-11 using Medicare data. Int J Radiat Oncol Biol Phys 2010 0.75
135 The 2007 Inaugural ASTRO/ASCO/AHNS Multidisciplinary Head and Neck Cancer Symposium. Int J Radiat Oncol Biol Phys 2007 0.75
136 Impact of changes to the American Joint Committee on Cancer T classification on outcome prediction in patients with oropharyngeal cancer. Cancer 2006 0.75
137 New equations for matching a low neck field to oblique upper neck fields with collimator rotation in a 3-field monoisocentric setup for head-and-neck cancers. Med Dosim 2004 0.75
138 Potential role of growth factors in diminishing radiation therapy neural tissue injury. Semin Oncol 2005 0.75
139 In response to Drs. Dubben, Beck-Bornholdt, and Llogie. Int J Radiat Oncol Biol Phys 2002 0.75
140 Intersociety Radiation Oncology Summit-SCOPE II. Int J Radiat Oncol Biol Phys 2008 0.75